The EV-302 trial (KEYNOTE-A39) OS and PFS benefit of Enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer

The combination reduced the risk of death by 49% and the risk of disease progression or death by 52% compared to chemotherapy, with mOS of 33.8 months versus 15.9 months

Confirmed objective response rate (cORR) was 67.5% for the combination versus 44.2% for chemotherapy, with a complete response achieved in 30.4% of patients versus 14.5%

The safety profile remained consistent, with fewer severe (grade ≥3) treatment-related adverse events in the enfortumab vedotin + pembrolizumab group (61.7%) compared to chemotherapy (71.9%)